Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs iShares MSCI South Korea ETF (EWY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs iShares MSCI South Korea ETF — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $284.59 (market cap $39.89B), while iShares MSCI South Korea ETF trades at $171.35. The key difference: iShares MSCI South Korea ETF is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | EWY | |
|---|---|---|
Market Cap | $39.89B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $491.22 | $219.20 |
52-Week Low | $278.09 | $70.65 |
Enterprise Value | $38.15B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
EWY, the iShares MSCI South Korea ETF, is trading at $183.52, down 0.62% amid bearish technical signals. The ETF faces headwinds from South Korea's Kospi Index entering a local bear market, declining 21% from its YTD high. Heavy concentration in Samsung and SK Hynix exposes EWY to AI chip volatility, with recent earnings pressure from weak EV demand at LG Energy Solution. Technical indicators show a bearish moving average crossover and ADX signaling strong downtrend momentum.
Despite the pullback, EWY remains a leveraged play on AI semiconductor demand through its top holdings. The outlook hinges on sustained AI memory demand and Samsung's performance, with potential upside from SK Hynix's planned U.S. listing. Key risks include single-stock concentration, global tech volatility, and Korea's delayed developed-market status. The current bearish trend suggests cautious entry points near support at $179-180 may offer better risk-reward.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About iShares MSCI South Korea ETF
EWY tracks the MSCI Korea 25/50 Index, offering targeted exposure to large and mid-cap companies in South Korea. It is structurally centered on the global technology supply chain, industrials, and financial services, serving as a liquid tool for investors seeking a single-country view of this advanced, innovation-led economy.
Read more on EWY →
